Avadel Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Avadel Pharmaceuticals has a total shareholder equity of $87.7M and total debt of $32.8M, which brings its debt-to-equity ratio to 37.3%. Its total assets and total liabilities are $164.7M and $77.0M respectively.
Key information
37.3%
Debt to equity ratio
US$32.76m
Debt
| Interest coverage ratio | n/a |
| Cash | US$105.11m |
| Equity | US$87.74m |
| Total liabilities | US$76.96m |
| Total assets | US$164.70m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: AWK1's short term assets ($134.2M) exceed its short term liabilities ($36.9M).
Long Term Liabilities: AWK1's short term assets ($134.2M) exceed its long term liabilities ($40.1M).
Debt to Equity History and Analysis
Debt Level: AWK1 has more cash than its total debt.
Reducing Debt: AWK1's debt to equity ratio has reduced from 4166.9% to 37.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AWK1 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AWK1 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.